CJC 1295 (without DAC) 5mg+IPA 5mg CP10 10mg*10vials

CJC 1295 (DAC-free) 5mg + IPA 5mg CP10 10mg*10 vials belongs to the CN peptide compound mixture and kit series. This product is a premixed lyophilized peptide mixture composed of equal proportions of CJC-1295 (DAC-free) and IPA. CJC-1295 (DAC-free) is a growth hormone-releasing hormone analog, while IPA is a helper peptide. This compound formulation combines the biological characteristics of two peptides, exhibiting zero immunogenicity, good solubility, and stable lyophilized activity. Each vial contains 10mg and is specifically designed for preclinical combined intervention studies, supporting research on growth hormone axis regulation, cell repair, body composition remodeling, and peptide synergistic effects. It is a core compound mixture research material for endocrine physiology and tissue repair mechanism studies.

Product Functions and Research Value

The CP10 compound formulation provides four core synergistic effects for laboratory research: CJC-1295 (DAC-free) stimulates pituitary growth hormone secretion, regulates GH-IGF-1 axis activity, and supports endocrine homeostasis research; IPA synergistically enhances cellular uptake signals, improves peptide utilization efficiency, and assists in tissue cell metabolic activation; both participate in energy metabolism regulation and explore body composition-related mechanisms; and exert biological effects related to tissue repair, providing experimental models for cell regeneration and damage repair research. GH-IGF-1 axis imbalance, low cellular material utilization, and slow tissue repair responses are common research topics in endocrinology and tissue physiology. This pre-formulated formulation avoids errors from manual mixing, provides stable combined pharmacological stimulation, and provides reproducible baseline data for preclinical studies of compound peptides.

Core Product Advantages

1. Pre-mixed fixed-ratio formulation: CJC-1295 (DAC-free) and IPA are pre-mixed and lyophilized in a 1:1 ratio, ready to use, eliminating the need for manual weighing and mixing, avoiding errors, and improving experimental consistency. 2. Growth Hormone Axis Regulation and Synergistic Absorption: CJC-1295 activates the growth hormone-insulin-like growth factor-1 axis; IPA improves the utilization rate of peptides at the cellular level, achieving synergistic intervention targeting two sites within a single vial.

3. Support for Metabolic and Tissue Repair Research: Suitable for research on mechanisms such as endocrine regulation, energy metabolism, and tissue cell repair.

4. Excellent Mixture Compatibility: The two peptide components exhibit good physicochemical compatibility after co-lyophilization, with stable activity and low impurity content.

5. Reliable Lyophilization Process: Adaptive gradient purification and vacuum lyophilization technology are used to process complex peptides to maintain the structural integrity of both active ingredients.

6. Standard Aseptic Quality Control Packaging: Each pack contains 10 vials, packaged in a dust-free and aseptic environment, analyzed by high-performance liquid chromatography (HPLC), and accompanied by a complete Certificate of Analysis (COA), suitable for laboratory complex peptide projects and bulk purchases.

CJC 1295 (DAC-free) 5mg + IPA 5mg CP10 10mg*10 vials is a premixed complex peptide from the CN complex peptide and kit series. CJC-1295 (DAC-free) is mixed with IPA in a 1:1 ratio for preclinical synergistic studies on GH-IGF-1 axis regulation, enhanced cellular uptake, energy metabolism, and tissue repair. Ready-to-use formulation, high purity, validated by high-performance liquid chromatography (HPLC), with a complete Certificate of Analysis (COA), available for wholesale.